Fusions between protein-coding genes are common oncogenic drivers across cancers, typically pairing a proto-oncogene with partner that does not independently drive cancer. In all therapeutically actionable fusions, the proto-oncogene is the drug target, the contributions to oncogenicity of the fusion partner have large...
Anna Borgenvik, Sean A. Misek, Daniel Christen et al.· bioRxiv· 1 citation
Early embryogenesis relies extensively on maternally deposited products until zygotic genome activation, yet the dynamics for the synthesis of new proteins in mammalian embryos remains poorly characterized. To address this, we applied pulsed stable isotope labelling by amino acids in cell culture (pSILAC) combined with...
L. Schmidt, Maico Y. Lechner, Javier Martín-González et al.· bioRxiv· 0 citations
Applied to very small human peripheral blood mononuclear cells, this work identifies up to 4000 proteins per cell, including key markers that distinguish monocytes, T cells, and activated lymphocytes within heterogeneous populations, underscoring that single-cell proteomics can now directly elucidate clinically relevan...
I. Hendriks, Sara C. Buch-Larsen, Martin Rykær et al.· Nature Communications· 2 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.